Turn Therapeutics Strengthens Leadership Team With Appointment Of Andrew Scott As Vice President Of Corporate Communications To Drive Capital Markets And Investor Strategy

Turn Therapeutics Inc., a clinical-stage biotechnology company focused on developing therapies for dermatologic conditions, advanced wound care, and infectious diseases, has announced the appointment of Andrew Scott as Vice President of Corporate Communications. In this newly created senior role, Scott will be responsible for overseeing investor relations, capital markets strategy, and corporate communications. He will also support the company’s licensing and partnership initiatives as Turn Therapeutics continues to expand its business and clinical development programs.

Bradley Burnam, Founder and Chief Executive Officer of Turn Therapeutics, expressed enthusiasm about Scott’s appointment, noting that it comes at a pivotal time for the company. “We are thrilled to welcome Andrew to this newly created senior executive role. His addition comes as Turn Therapeutics enters a new phase of growth following its public listing and strengthened balance sheet. 

Andrew brings a wealth of experience that will help guide us as a public company, expand our investor engagement, and ensure our story reaches the right audiences as we approach several important milestones in the coming year, including the completion of our Phase 2 clinical program,” Burnam said. He added that Scott’s expertise will play a key role in advancing the company’s partnership efforts and clinical progress.

Andrew Scott brings more than 30 years of experience in capital markets and corporate finance to his new role. Before joining Turn Therapeutics, he served as Managing Director of Investment Banking at ThinkEquity LLC, where he played a leading role in advising and executing financial transactions across the life sciences sector. Previously, he was Vice President of Business Development at Fortress Biosciences, Inc. Over the course of his career, Scott has been instrumental in helping raise approximately $3 billion through a range of transactions within the biotechnology and healthcare industries. He holds a Bachelor of Business Administration degree in Accounting from Pace University.